Fundraising Fox

EnteroBiotix

Glasgow · 1 known investors

EnteroBiotix is a clinical-stage microbiome therapeutics company developing EBX-102-02, an orally delivered, full-spectrum microbiome drug for irritable bowel syndrome and other gastrointestinal and liver diseases. It uses proprietary AMPLA drying technology and MHRA-licensed GMP manufacturing, with a pipeline spanning IBS, liver cirrhosis, and adjuvant treatment in blood cancer.</parameter> <parameter name="founders">[]

BiotechHealthtech

Founders & leadership

JRJames Roger McIlroy
James Roger McIlroyFounder
MS
Melissa StrangeExecutive
JBJames Barnes
James BarnesExecutive

Board

DC
Douglas Campbell ThomsonBoard director
FA
Felix Andy Awili OlaleBoard director
IB
Iain BairdBoard director
MB
Mark BamforthBoard director
EJ
Elmar Josef SchneeBoard director
DL
David LawrenceBoard director

Investors · 1

Scottish National Investment BankEdinburgh · $1.3M

Reported raises · per SEC filings

Form D private placements

$28.5M disclosed across 6 rounds · 2022–2026

▶$5.3MraisedApr 2026 · 6 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Iain BairdDirector
  • Strange MelissaExecutive Officer
  • Elmar Josef SchneeDirector
  • Mark BamforthDirector
  • James Roger McIlroyExecutive Officer, Director
  • Douglas Campbell ThomsonDirector
  • Barnes JamesExecutive Officer
Amount sold
$5.3M
First sale
Mar 2026
Incorporated
Other, United Kingdom
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.4MraisedJul 2025 · 2 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Elmar Josef SchneeDirector
  • Douglas Campbell ThomsonDirector
  • Felix Andy Awili OlaleDirector
  • Iain BairdDirector
  • Melissa StrangeExecutive Officer
  • Mark BamforthDirector
  • James BarnesExecutive Officer
  • David LawrenceDirector
  • James Roger McIlroyExecutive Officer, Director
Amount sold
$1.4M
Minimum investment
$33.9K
First sale
Jul 2025
Incorporated
Other, United Kingdom
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.3MraisedApr 2024 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Iain BairdDirector
  • Mark BamforthDirector, Promoter
  • David LawrenceDirector
  • Christopher LeaExecutive Officer, Director
  • Elmar SchneeDirector
  • Douglas ThomsonDirector
  • James McIlroyExecutive Officer, Director
Amount sold
$1.3M
Minimum investment
$1.3M
First sale
Mar 2024
Incorporated
Other, United Kingdom
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.6MraisedFeb 2024 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Elmar SchneeDirector
  • Mark BamforthDirector, Promoter
  • Christopher LeaExecutive Officer
  • Iain BairdDirector
  • David LawrenceDirector
  • Douglas ThomsonDirector
  • James McIlroyExecutive Officer, Director
Amount sold
$2.6M
Minimum investment
$31.8K
First sale
Jan 2024
Incorporated
Other, United Kingdom
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$6.7MraisedAug 2023 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Mark BamforthDirector, Promoter
  • James McIlroyExecutive Officer, Director
  • Elmar SchneeDirector
  • Iain BairdDirector
  • David LawrenceDirector
  • Douglas ThomsonDirector
Amount sold
$6.7M
Minimum investment
$127.6K
First sale
Aug 2023
Incorporated
Limited Liability Company, United Kingdom
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$11.2MraisedSep 2022 · 5 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Iain J. BairdDirector
  • Douglas Campbell ThomsonDirector
  • David Muir LawrenceDirector
  • James Roger McIlroyExecutive Officer, Director, Promoter
  • Mark R. BamforthDirector, Promoter
Offering amount
$13M
Amount sold
$11.2M
Minimum investment
$117K
First sale
Aug 2022
Incorporated
Limited Liability Company, United Kingdom
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap
Nanobiotix5 shared keywordsNanobiotix develops physics-based nanotherapeutics for cancer treatment, applying nanotechnology to expand therapeutic options for oncology patients. The company builds on French scientific research and targets patients worldwide through disruptive treatment approaches.

Companies competing with EnteroBiotix for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does EnteroBiotix do?
EnteroBiotix is a clinical-stage microbiome therapeutics company developing EBX-102-02, an orally delivered, full-spectrum microbiome drug for irritable bowel syndrome and other gastrointestinal and liver diseases. It uses proprietary AMPLA drying technology and MHRA-licensed GMP manufacturing, with a pipeline spanning IBS, liver cirrhosis, and adjuvant treatment in blood cancer.</parameter> <parameter name="founders">[]
Who founded EnteroBiotix?
EnteroBiotix was founded by James Roger McIlroy.
Who are EnteroBiotix's investors?
EnteroBiotix's investors include Scottish National Investment Bank.
How much funding has EnteroBiotix raised?
EnteroBiotix has disclosed $28.5M raised across 6 rounds.
Where is EnteroBiotix headquartered?
EnteroBiotix is headquartered in Glasgow.